Evidence map›Paper›PMID 38201519›Full record

ArticleCancers2023

First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors.

Anna R Schreiber, Jodi A Kagihara, Bradley R Corr, S Lindsey Davis, Christopher Lieu, Sunnie S Kim, Antonio Jimeno, D Ross Camidge, Jud Williams, Amy M Heim and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Clinical progress and functional modalities of HDAC inhibitor-based combination therapies in cancer treatment.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 1 country.

Anna R SchreiberDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID 0000-0003-2136-2476
Jodi A KagiharaDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Bradley R CorrDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
S Lindsey DavisDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Christopher LieuDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID 0000-0002-4852-4642
Sunnie S KimDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID 0009-0008-3871-5112
Antonio JimenoDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
D Ross CamidgeDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Jud WilliamsOnKure, Inc., Boulder, CO 80301, USA.
Amy M HeimOnKure, Inc., Boulder, CO 80301, USA.
Anne MartinDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
John A DeMatteiOnKure, Inc., Boulder, CO 80301, USA.
Nisha HolayLivestrong Cancer Institutes, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, TX 78712, USA.
Todd A TriplettLivestrong Cancer Institutes, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, TX 78712, USA.
S Gail EckhardtLivestrong Cancer Institutes, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, TX 78712, USA.
Kevin LitwilerOnKure, Inc., Boulder, CO 80301, USA.
James WinklerOnKure, Inc., Boulder, CO 80301, USA.
Anthony D PiscopioOnKure, Inc., Boulder, CO 80301, USA.
Jennifer R DiamondDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
University of Colorado Anschutz Medical Campus · USLivestrong Foundation · USTexas Tech University · USUniversity of Hawaiʻi at Mānoa · US

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
NCI NIH HHS P30 CA046934
6 · The paper itself

Abstract

(1) Background: Histone deacetylases (HDACs) play a critical role in epigenetic signaling in cancer; however, available HDAC inhibitors have limited therapeutic windows and suboptimal pharmacokinetics (PK). This first-in-human phase I dose escalation study evaluated the safety, PK, pharmacodynamics (PDx), and efficacy of the oral Class I-targeting HDAC inhibitor bocodepsin (OKI-179). (2) Patients and Methods: Patients (

Indexed as

HDAC inhibitorsMEK inhibitorsphase I clinical trialsolid tumors

Identifiers

PMID38201519
PMCPMC10778198
OpenAlexW4390175004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.